HK1081194A1 - 6-amino-1h-indazole compounds as phosphodiesterase4 inhibitors, pharmaceutical compositions compris ing the same, and use thereof - Google Patents

6-amino-1h-indazole compounds as phosphodiesterase4 inhibitors, pharmaceutical compositions compris ing the same, and use thereof

Info

Publication number
HK1081194A1
HK1081194A1 HK06101282A HK06101282A HK1081194A1 HK 1081194 A1 HK1081194 A1 HK 1081194A1 HK 06101282 A HK06101282 A HK 06101282A HK 06101282 A HK06101282 A HK 06101282A HK 1081194 A1 HK1081194 A1 HK 1081194A1
Authority
HK
Hong Kong
Prior art keywords
inhibitors
amino
pharmaceutical compositions
same
compris ing
Prior art date
Application number
HK06101282A
Other languages
English (en)
Inventor
Richard Schumacher
Allan Hopper
Ashok Tehim
Original Assignee
Memory Pharm Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memory Pharm Corp filed Critical Memory Pharm Corp
Publication of HK1081194A1 publication Critical patent/HK1081194A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Psychology (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Furan Compounds (AREA)
HK06101282A 2002-07-19 2006-01-27 6-amino-1h-indazole compounds as phosphodiesterase4 inhibitors, pharmaceutical compositions compris ing the same, and use thereof HK1081194A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39672602P 2002-07-19 2002-07-19
PCT/US2003/022401 WO2004009557A1 (en) 2002-07-19 2003-07-18 6-amino-1h-indazole and 4-aminobenzofuran compounds as phosphodiesterase 4 inhibitors

Publications (1)

Publication Number Publication Date
HK1081194A1 true HK1081194A1 (en) 2006-05-12

Family

ID=30770939

Family Applications (1)

Application Number Title Priority Date Filing Date
HK06101282A HK1081194A1 (en) 2002-07-19 2006-01-27 6-amino-1h-indazole compounds as phosphodiesterase4 inhibitors, pharmaceutical compositions compris ing the same, and use thereof

Country Status (20)

Country Link
US (2) US7655802B2 (ru)
EP (1) EP1549619B1 (ru)
JP (1) JP2006502995A (ru)
CN (2) CN101423497A (ru)
AT (1) ATE421505T1 (ru)
AU (2) AU2003256601B2 (ru)
BR (1) BR0313000A (ru)
CA (1) CA2492911A1 (ru)
CO (1) CO5680420A2 (ru)
DE (1) DE60325984D1 (ru)
ES (1) ES2323688T3 (ru)
HK (1) HK1081194A1 (ru)
HR (1) HRP20050082A2 (ru)
IL (1) IL166164A0 (ru)
MX (1) MXPA05000825A (ru)
NO (1) NO20050871L (ru)
NZ (1) NZ537725A (ru)
RU (1) RU2354648C2 (ru)
WO (1) WO2004009557A1 (ru)
ZA (1) ZA200500436B (ru)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7135575B2 (en) 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
GB0402262D0 (en) * 2004-02-02 2004-03-10 Novartis Ag Process for the manufacture of organic compounds
JP2008542332A (ja) * 2005-05-31 2008-11-27 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 呼吸器疾患治療用新規医薬組成物
CN101415685B (zh) 2006-01-31 2011-08-24 阿雷生物药品公司 激酶抑制剂及其使用方法
SI2178870T1 (sl) 2007-08-17 2018-11-30 Lg Chem, Ltd. Indolne in indazolne spojine kot inhibitor celične nekroze
US9891783B2 (en) * 2007-09-26 2018-02-13 Autodesk, Inc. Navigation system for a 3D virtual scene
WO2009070921A1 (en) * 2007-11-30 2009-06-11 Chi, Yu-Fen Antimelancholic medicine prepared with jujube camp materials
US20150119399A1 (en) 2012-01-10 2015-04-30 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
JP5857168B2 (ja) * 2012-11-08 2016-02-10 ファイザー・インク ドーパミンｄ１リガンドとしての複素芳香族化合物およびその使用
US9856263B2 (en) 2014-04-28 2018-01-02 Pfizer Inc. Heteroaromatic compounds and their use as dopamine D1 ligands

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE580519C (de) * 1932-02-26 1933-07-12 I G Farbenindustrie Akt Ges Verfahren zur Darstellung von 2-Oxy-3-arylaminonaphthalinen
US3259623A (en) 1963-06-14 1966-07-05 Olin Mathieson Process for preparing 2-(secondary amino)-halogenopyrimidines
GB1337389A (en) 1969-12-10 1973-11-14 Ici Ltd Pyrimidine derivatives
US3755332A (en) * 1971-07-01 1973-08-28 Ciba Geigy Corp Substituted 4 indazolaminoquinolines
FR2244520B1 (ru) 1973-07-06 1977-02-04 Ugine Kuhlmann
US4524373A (en) 1982-02-24 1985-06-18 Kanzaki Paper Manufacturing Co., Ltd. Fluoran derivatives as new compounds, process for preparing the same and recording system utilizing the same as colorless chromogenic material
GB2202434B (en) * 1987-03-25 1990-03-28 Tachi S Co Apparatus for manufacturing a seat
US5221682A (en) * 1989-06-28 1993-06-22 Hoechst-Roussel Pharmaceuticals Incorporated Heteroarylamino- and heteroaryloxypyridinamines and related compounds
US5935978A (en) * 1991-01-28 1999-08-10 Rhone-Poulenc Rorer Limited Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic- or heteroatom-containing linking group
GB9311281D0 (en) * 1993-06-01 1993-07-21 Rhone Poulenc Rorer Ltd Novel composition of matter
US5698711A (en) * 1991-01-28 1997-12-16 Rhone-Poulenc Rorer Limited Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic- or heteroatom-containing linking group
US5204226A (en) 1991-03-04 1993-04-20 International Business Machines Corporation Photosensitizers for polysilanes
US5204366A (en) 1991-06-10 1993-04-20 American Cyanamid Company 2,5-dioxo-3-pyrroline-1-acetanilide fungicidal agents, compositions and method for use thereof
US6096768A (en) * 1992-01-28 2000-08-01 Rhone-Poulenc Rorer Limited Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic- or heteroatom-containing linking group
ATE150447T1 (de) 1992-06-15 1997-04-15 Celltech Therapeutics Ltd Trisubstituierte phenylderivate als selektive phosphodiesterase iv inhibitoren
US5679696A (en) * 1992-07-28 1997-10-21 Rhone-Poulenc Rorer Limited Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic-or heteroatom-containing linking group
WO1994002465A1 (en) 1992-07-28 1994-02-03 Rhone-Poulenc Rorer Limited INHIBITORS OF c-AMP PHOSPHODIESTERASE AND TNF
US5814651A (en) * 1992-12-02 1998-09-29 Pfizer Inc. Catechol diethers as selective PDEIV inhibitors
GB9323290D0 (en) * 1992-12-10 1994-01-05 Zeneca Ltd Quinazoline derivatives
TW263495B (ru) 1992-12-23 1995-11-21 Celltech Ltd
US5622977A (en) * 1992-12-23 1997-04-22 Celltech Therapeutics Limited Tri-substituted (aryl or heteroaryl) derivatives and pharmaceutical compositions containing the same
GB9304919D0 (en) * 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
GB9304920D0 (en) * 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
WO1994027971A1 (en) 1993-05-27 1994-12-08 Smithkline Beecham Laboratoires Pharmaceutiques Anti-arrhythmic n-substituted 3-benzazepines or isoquinolines
DK0706513T3 (da) * 1993-07-02 2002-09-09 Altana Pharma Ag Fluoralkoxysubstituerede benzamider og anvendelse deraf som cyklisk-nukleotid phosphodiesteraseinhibitorer
GB9315595D0 (en) 1993-07-28 1993-09-08 Res Inst Medicine Chem New compounds
JPH07206789A (ja) 1993-09-01 1995-08-08 Taisho Pharmaceut Co Ltd コンブレタスタチン類縁化合物
AU692484B2 (en) 1993-10-12 1998-06-11 Du Pont Pharmaceuticals Company 1N-alkyl-N-arylpyrimidinamines and derivatives thereof
ATE260911T1 (de) * 1993-12-22 2004-03-15 Celltech R&D Ltd Trisubstituierte phenyl-derivate, verfahren zu deren herstellung und deren verwendung als phosphodiesterase (typ iv) hemmstoffe
GB9326600D0 (en) * 1993-12-22 1994-03-02 Celltech Ltd Chemical compounds
GB9401460D0 (en) 1994-01-26 1994-03-23 Rhone Poulenc Rorer Ltd Compositions of matter
US6245774B1 (en) * 1994-06-21 2001-06-12 Celltech Therapeutics Limited Tri-substituted phenyl or pyridine derivatives
US5786354A (en) 1994-06-21 1998-07-28 Celltech Therapeutics, Limited Tri-substituted phenyl derivatives and processes for their preparation
GB9412573D0 (en) * 1994-06-22 1994-08-10 Celltech Ltd Chemical compounds
GB9412571D0 (en) * 1994-06-22 1994-08-10 Celltech Ltd Chemical compounds
GB9412672D0 (en) * 1994-06-23 1994-08-10 Celltech Ltd Chemical compounds
US5591776A (en) 1994-06-24 1997-01-07 Euro-Celtique, S.A. Pheynl or benzyl-substituted rolipram-based compounds for and method of inhibiting phosphodiesterase IV
FR2729142A1 (fr) 1995-01-06 1996-07-12 Smithkline Beecham Lab Nouvelles amines heterocycliques, leur procede de preparation et leur utilisation en tant que medicaments et notamment en tant qu'agents anti-arythmiques
US5731477A (en) 1995-01-31 1998-03-24 Smithkline Beecham Corporation Method for synthesis of aryl difluoromethyl ethers
IT1275433B (it) 1995-05-19 1997-08-07 Smithkline Beecham Farma Derivati di diarildiammine
AU5772196A (en) * 1995-05-19 1996-11-29 Chiroscience Limited 3,4-disubstituted-phenylsulphonamides and their therapeutic use
FR2735777B1 (fr) * 1995-06-21 1997-09-12 Sanofi Sa Derives de 4-phenylaminothiazole, leur procede de preparation et les compositions pharmaceutiques les contenant
US5935966A (en) 1995-09-01 1999-08-10 Signal Pharmaceuticals, Inc. Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions
US5710170A (en) * 1995-12-15 1998-01-20 Merck Frosst Canada, Inc. Tri-aryl ethane derivatives as PDE IV inhibitors
GB9603723D0 (en) * 1996-02-22 1996-04-24 Merck & Co Inc Diphenyl pyridyl derivatives as pde iv inhibitors
GB9526245D0 (en) * 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Chemical compounds
GB9526243D0 (en) * 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Chemical compounds
GB9526246D0 (en) * 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Chemical compounds
CA2258285C (en) * 1996-06-25 2002-11-26 Anthony Marfat Substituted indazole derivatives and their use as phosphodiesterase (pde) type iv and tumor necrosis factor (tnf) inhibitors
AU724549B2 (en) * 1996-09-04 2000-09-28 Pfizer Inc. Indazole derivatives and their use as inhibitors of phosphodiesterase (PDE) type IV and the production of tumor necrosis factor (TNF)
GB9625184D0 (en) * 1996-12-04 1997-01-22 Celltech Therapeutics Ltd Chemical compounds
CA2295106C (en) 1997-06-24 2007-03-13 Nikken Chemicals Co., Ltd. 3-anilino-2-cycloalkenone derivatives
US5919937A (en) * 1997-10-29 1999-07-06 Merck & Co., Inc. Process for phosphodiesterase IV inhibitors
DK1045690T3 (da) * 1997-11-25 2003-08-04 Warner Lambert Co Benzensulfonamidinhibitorer af PDE-IV og deres terapeutiske anvendelse
WO1999033806A1 (en) 1997-12-24 1999-07-08 Ortho-Mcneil Pharmaceutical, Inc. 4-[aryl(piperidin-4-yl)] aminobenzamides which bind to the delta-opioid receptor
JP3542482B2 (ja) 1997-12-25 2004-07-14 日研化学株式会社 ３−アニリノ−２−シクロアルケノン誘導体
CA2344169C (en) * 1998-09-29 2011-07-19 American Cyanamid Company Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors
EP1157007A1 (en) * 1999-02-25 2001-11-28 Merck Frosst Canada Inc. Pde iv inhibiting compounds, compositions and methods of treatment
US6180650B1 (en) 1999-04-23 2001-01-30 Merck Frosst Canada & Co. Heterosubstituted pyridine derivatives as PDE 4 inhibitors
US6200993B1 (en) * 1999-05-05 2001-03-13 Merck Frosst Canada & Co. Heterosubstituted pyridine derivatives as PDE4 inhibitors
GB2350110A (en) * 1999-05-17 2000-11-22 Bayer Ag Pharmaceutically active benzofurans
RU2331640C2 (ru) 1999-05-21 2008-08-20 Бристол-Маерс Сквибб Ко. Пирролтриазиновые ингибиторы киназ
JP4434362B2 (ja) * 1999-06-28 2010-03-17 興和創薬株式会社 ホスホジエステラーゼ阻害剤
GB9918035D0 (en) * 1999-07-30 1999-09-29 Novartis Ag Organic compounds
MXPA02003436A (es) 1999-10-07 2002-08-20 Amgen Inc Inhibidores de triazina cinasa.
WO2001038306A1 (en) * 1999-11-27 2001-05-31 Dong Wha Pharm. Ind. Co., Ltd Novel 3-nitropyridine derivatives and the pharmaceutical compositions containing said derivatives
DE50011851D1 (de) 1999-12-18 2006-01-19 Wella Ag 2-Aminoalkyl-1,4-diaminobenzol-Derivate und diese Verbindungen enthaltende Färbemittel
MY123585A (en) 2000-03-23 2006-05-31 Merck Canada Inc Tri-aryl-substituted-ethane pde4 inhibitors.
SI1343782T1 (sl) * 2000-12-21 2009-10-31 Smithkline Beecham Corp Pirimidinamini kot modulatorji angiogeneze
US6699890B2 (en) * 2000-12-22 2004-03-02 Memory Pharmaceuticals Corp. Phosphodiesterase 4 inhibitors
US7153871B2 (en) * 2001-01-22 2006-12-26 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors, including aminoindazole and aminobenzofuran analogs
AU2002303078B2 (en) 2001-01-22 2007-08-30 Memory Pharmaceuticals Corporation Aniline derivatives useful as phosphodiesterase 4 inhibitors
US7205320B2 (en) 2001-01-22 2007-04-17 Memory Pharmaceuticals Corp. Phosphodiesterase 4 inhibitors
US20030130264A1 (en) 2001-02-16 2003-07-10 Tularik Inc. Methods of using pyrimidine-based antiviral agents
US20030149052A1 (en) 2002-01-22 2003-08-07 Memory Pharmaceuticals Corp. Phosphodiesterase 4 inhibitors
BR0312999A (pt) 2002-07-19 2005-06-07 Memory Pharm Corp Compostos, composições farmacêticas, método para aumentar a cognição, de tratamento, de inibição da atividade de enzima pde4 em um paciente
CA2506297A1 (en) 2002-11-19 2004-06-03 Memory Pharmaceuticals Corporation Pyridine n-oxide compounds as phosphodiesterase 4 inhibitors
MY141255A (en) 2003-12-11 2010-03-31 Memory Pharm Corp Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs

Also Published As

Publication number Publication date
BR0313000A (pt) 2005-07-12
AU2003256601B2 (en) 2009-10-29
NO20050871L (no) 2005-02-18
EP1549619B1 (en) 2009-01-21
ATE421505T1 (de) 2009-02-15
US20070123570A1 (en) 2007-05-31
DE60325984D1 (de) 2009-03-12
US20100093806A1 (en) 2010-04-15
CN101423497A (zh) 2009-05-06
CO5680420A2 (es) 2006-09-29
CN1668602A (zh) 2005-09-14
ZA200500436B (en) 2006-07-26
MXPA05000825A (es) 2005-08-29
CA2492911A1 (en) 2004-01-29
EP1549619A1 (en) 2005-07-06
RU2354648C2 (ru) 2009-05-10
HRP20050082A2 (en) 2005-06-30
JP2006502995A (ja) 2006-01-26
RU2005104820A (ru) 2005-10-10
ES2323688T3 (es) 2009-07-23
NZ537725A (en) 2006-08-31
US7655802B2 (en) 2010-02-02
IL166164A0 (en) 2006-01-15
AU2010200233A1 (en) 2010-02-11
CN100381425C (zh) 2008-04-16
WO2004009557A1 (en) 2004-01-29
AU2003256601A1 (en) 2004-02-09

Similar Documents

Publication Publication Date Title
HK1081194A1 (en) 6-amino-1h-indazole compounds as phosphodiesterase4 inhibitors, pharmaceutical compositions compris ing the same, and use thereof
TW200602322A (en) Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs
DE602004008098D1 (de) Substituierte 2h-ä1,2,4ütriazoloä4,3-aüpyrazine als gsk-3-inhibitoren
ATE449099T1 (de) Derivate des 2-trifluormethyl-6-aminopurins als phosphodiesterase 4 inhibitoren
YU57603A (sh) Inhibitori fosfodiesteraze 4
NO20082346L (no) Hydrazonderivater og anvendelser derav
MXPA05009969A (es) Metodo para aislar la forma cristalina i de la 5-azacitidina.
NO20070557L (no) Ftalazinderivater som PARP-inhibitorer
NO20070555L (no) Kinazolinonderivater som parp-inhibitorer
ATE433447T1 (de) Pyrimiidinverbindungen
CY1107747T1 (el) Υποκατεστημενα τετρακυκλικα παραγωγα πυρρολοκινολονης χρησιμα ως αναστολεις της φωσφοδιεστερασης
NO20070224L (no) 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
NO20050870L (no) Fosfodiesterase 4-inhibitorer, inkludert N-substituerte anilin- og difenylaminanaloger
EA200700185A1 (ru) Производные хиназолиндиона в качестве ингибиторов parp
EA200601007A1 (ru) 7-фенилалкилзамещённые 2-хинолиноны и 2-хиноксалиноны в качестве ингибиторов поли(адф-рибоза)полимеразы
MXPA05011411A (es) 1,4-diazepinas sustituidas y usos de las mismas.
IL173810A0 (en) Imidazopyridine derivatives and pharmaceutical compositions containing the same
WO2006047415A3 (en) FACTOR Xa COMPOUNDS
MXPA05012247A (es) Derivados de bencimidazol nuevos.
HRP20070286T3 (en) Substituted diketopiperazines and their use as oxytocyn antagonists
TW200628153A (en) Novel compounds
DE60314381D1 (de) Benzylimidazolyl substituierte 2-chinolon und chinazolinon derivate zur verwendung als farnesyl transferase inhibitoren
RS79703A (en) Phenyl heterocyclyl ether derivatives as serotonin re-uptake inhibitors
GB0327323D0 (en) Novel pharmaceuticals
ATE419242T1 (de) Pyrrolidinylharnstoffderivate als angiogeneseinhibitoren

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20120718